Compare LWLG & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LWLG | KROS |
|---|---|---|
| Founded | 1991 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 578.6M | 655.9M |
| IPO Year | N/A | 2020 |
| Metric | LWLG | KROS |
|---|---|---|
| Price | $3.86 | $18.58 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $22.20 |
| AVG Volume (30 Days) | ★ 2.3M | 564.7K |
| Earning Date | 11-14-2025 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.57 |
| Revenue | $100,605.00 | ★ $246,718,000.00 |
| Revenue This Year | N/A | $6,924.79 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $11.30 |
| Revenue Growth | N/A | ★ 37798.31 |
| 52 Week Low | $0.79 | $9.12 |
| 52 Week High | $6.26 | $22.55 |
| Indicator | LWLG | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 54.26 | 42.98 |
| Support Level | $3.09 | $17.51 |
| Resistance Level | $4.00 | $21.76 |
| Average True Range (ATR) | 0.24 | 0.80 |
| MACD | 0.12 | -0.50 |
| Stochastic Oscillator | 91.38 | 24.94 |
Lightwave Logic Inc is a United States-based development stage company moving toward commercialization of next-generation electro-optic photonic devices made on its P2IC technology platform which uses in-house proprietary high-activity and high-stability organic polymers. Electro-optical devices convert data from electric signals into optical signals for multiple applications. It designs and synthesizes organic chromophores for use in its own proprietary electro-optic polymer systems and photonic device designs.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.